活性菌制剂联合降糖药物治疗新诊断2型糖尿病患者的疗效

Efficacy Evaluation of Bifidobacterium Lactobacillus Triple Live Tablet Combined With Hypoglycemic Medicine in the Treatment of Newly Diagnosed Type 2 Diabetes Patients

目的研究双歧杆菌乳杆菌三联活菌片联合甘精胰岛素、阿卡波糖治疗新诊断2型糖尿病(T2DM)的效果。方法选取2018年6月—2020年6月本院新诊断T2DM患者224例,按照随机数字表法分为常规组、研究组,各112例。常规组采用甘精胰岛素、阿卡波糖治疗,研究组在常规组基础上采用双歧杆菌乳杆菌三联活菌片治疗。比较两组疗效、血糖水平[空腹血糖(FBG)、餐后2 h血糖(2 h PBG)、糖化血红蛋白(HbA1c)]、肠道菌群水平(双歧杆菌、乳杆菌、大肠埃希菌)及血清Toll样受体4(recombinant toll like receptor 4,TLR4)、高迁移率族蛋白1(high mobility group box-1 protein,HMGB1)水平。结果研究组总有效率90.18%,高于常规组80.36%(P<0.05);治疗3个月后研究组FBG、2 h PBG、HbA1c低于常规组(P<0.05);治疗3个月后研究组双歧杆菌、乳杆菌高于常规组,大肠埃希菌低于常规组(P<0.05);治疗3个月后研究组血清TLR4、HMGB1水平低于常规组(P<0.05)。结论双歧杆菌乳杆菌三联活菌片联合甘精胰岛素、阿卡波糖治疗新诊断T2DM疗效显著,能降低血糖水平,调节肠道菌群,改善血清TLR4、HMGB1水平。

Objective To study the effect of bifidobacterium lactobacillus triple live tablet combined with hypoglycemic medicine in the treatment of newly diagnosed type 2 diabetes mellitus(T2DM).Methods A total of 224 newly diagnosed T2DM patients in our hospital from June 2018 to June 2020 were selected and divided into routine group and study group according to random number table method,with 112 cases in each group.The conventional group was treated with insulin glargine and acarbose,while the research group was treated with bifidobacterium and lactobacillus triple live tablet on the basis of conventional group.The efficacy,blood glucose level(FBG,2 h PBG,HbA1c),intestinal flora level(Bifidobacterium,Lactobacillus,Escherichia coli),recombinant toll like receptor 4(TLR4)and high mobility group box-1 protein(HMGB1)levels were compared between the two groups.Results The total effective rate of study group was 90.18%,higher than 80.36%of conventional group(P<0.05).After 3 months of treatment,FBG,2 h PBG and HbA1c in the study group were lower than those in the conventional group(P<0.05).After 3 months of treatment,Bifidobacterium and Lactobacillus in the study group were higher than those in the conventional group,and Escherichia coli were lower than those in the conventional group(P<0.05).After 3 months of treatment,serum TLR4 and HMGB1 levels in the study group were lower than those in the conventional group(P<0.05).Conclusion Bifidobacterium and lactobacillus triple live tablet combined with insulin glargine and acarbose has significant efficacy in the treatment of newly diagnosed T2DM,which can reduce blood glucose level,regulate intestinal flora,and improve serum TLR4 and HMGB1 levels.